Chemotherapy combination with monoclonal antibody

0 marketed 2 in Phase 3

This page covers all Chemotherapy combination with monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting EGFR (epidermal growth factor receptor), CD20 (rituximab component); DNA/topoisomerase II (chemotherapy components).

Targets

EGFR (epidermal growth factor receptor) · CD20 (rituximab component); DNA/topoisomerase II (chemotherapy components)

Phase 3 pipeline (2)

Arm D: FOLFIRI or FOLFOX plus CETUXIMAB · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Oncology
This combination regimen uses chemotherapy (FOLFIRI or FOLFOX) to kill rapidly dividing cancer cells, combined with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to prevent tumor growth.
R-CHOEP 14 with 12x Rituximab · German High-Grade Non-Hodgkin's Lymphoma Study Group · Oncology
R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction.